Table 2 Statistical validation analysis for the proposed multi-disciplinary algorithm
Group | TP | FP | TN | FN | Prevalence | Sensitivity | Specificity | PPV | NPV | Accuracy | Balanced accuracy | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Value | 95% CI | Value | 95% CI | ||||||||||
Interstitial fibrosing diseases: | |||||||||||||
IPF | 23 | 0 | 77 | 0 | 23% | 100% | 85.18% to 100.00% | 100% | 95.32% to 100.00% | 100% | 100% | 100% | 1 |
Fibrosing NSIP | 18 | 3 | 78 | 1 | 19% | 94.7% | 73.97% to 99.87% | 96.3% | 89.56% to 99.23% | 85.7% | 98.7% | 96.00% | 0.955 |
Chronic HP | 15 | 1 | 81 | 3 | 18% | 83.3% | 58.58% to 96.42% | 98.8% | 93.39% to 99.97% | 93.8% | 96.4% | 96.00% | 0.91 |
PPFE | 0 | 2 | 98 | 0 | 0% | NA | NA | 98.0% | 92.96% to 99.76% | NA | 100% | NA | NA |
Non-interstitial fibrosing diseases | |||||||||||||
Post-TB fibrosis | 15 | 0 | 83 | 2 | 17% | 88.2% | 63.56% to 98.54% | 100% | 95.65% to 100.00% | 100% | 97.7% | 98.00% | 0.94 |
Post-irradiation fibrosis | 14 | 0 | 86 | 0 | 14% | 100% | 75.29% to 100.00% | 100% | 95.85% to 100.00% | 100% | 100% | 100% | 1 |
Fibrosing sarcoidosis | 6 | 0 | 94 | 0 | 6% | 100% | 54.07% to 100.00% | 100% | 96.15% to 100.00% | 100% | 100% | 100% | 1 |
PMF | 3 | 0 | 97 | 0 | 3% | 100% | 29.24% to 100.00% | 100% | 96.27% to 100.00% | 100% | 100% | 100% | 1 |
Complications of lung fibrosis | |||||||||||||
Malignancy | 2 | 0 | 98 | 0 | 2% | 100% | 15.81% to 100.00% | 100% | 96.31% to 100.00% | 100% | 100% | 100% | 1 |